NCT03770494 2025-11-04
A Study of LY3405105 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Terminated
Eli Lilly and Company
Massachusetts General Hospital
Bristol-Myers Squibb
BioNTech SE
Memorial Sloan Kettering Cancer Center
Gilead Sciences